ArTS Archivio della ricerca di Trieste

FEDERICO, STEPHANIE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.914
EU - Europa 4.893
AS - Asia 4.245
SA - Sud America 523
AF - Africa 168
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
AN - Antartide 1
Totale 19.777
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.731
SG - Singapore 1.539
IT - Italia 1.107
CN - Cina 959
SE - Svezia 845
PL - Polonia 518
BR - Brasile 418
DE - Germania 386
HK - Hong Kong 373
VN - Vietnam 368
NL - Olanda 355
FR - Francia 342
UA - Ucraina 278
KR - Corea 260
GB - Regno Unito 242
FI - Finlandia 201
RU - Federazione Russa 192
IN - India 160
TR - Turchia 140
BD - Bangladesh 126
IE - Irlanda 104
CA - Canada 98
BG - Bulgaria 78
JP - Giappone 51
BE - Belgio 45
MA - Marocco 42
IQ - Iraq 41
AT - Austria 38
ES - Italia 37
ID - Indonesia 36
CH - Svizzera 35
CZ - Repubblica Ceca 32
AR - Argentina 31
MX - Messico 27
PK - Pakistan 25
CI - Costa d'Avorio 23
MY - Malesia 22
SA - Arabia Saudita 21
EC - Ecuador 20
EG - Egitto 20
ZA - Sudafrica 20
UZ - Uzbekistan 18
CO - Colombia 17
IL - Israele 16
AU - Australia 15
LT - Lituania 15
AZ - Azerbaigian 12
JM - Giamaica 12
KE - Kenya 12
EU - Europa 11
VE - Venezuela 11
CL - Cile 10
JO - Giordania 10
BZ - Belize 9
PH - Filippine 9
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
IR - Iran 8
HN - Honduras 7
NG - Nigeria 7
SN - Senegal 7
TG - Togo 7
TN - Tunisia 7
PE - Perù 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
NZ - Nuova Zelanda 5
PT - Portogallo 5
TH - Thailandia 5
AL - Albania 4
BB - Barbados 4
BY - Bielorussia 4
CR - Costa Rica 4
ET - Etiopia 4
HU - Ungheria 4
KZ - Kazakistan 4
NO - Norvegia 4
OM - Oman 4
PR - Porto Rico 4
RS - Serbia 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
BO - Bolivia 3
GR - Grecia 3
LV - Lettonia 3
MN - Mongolia 3
PY - Paraguay 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
DK - Danimarca 2
GE - Georgia 2
GT - Guatemala 2
KG - Kirghizistan 2
KW - Kuwait 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
SI - Slovenia 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 19.747
Salva come PNG Salva come JPEG
Città #
Dallas 2.477
Singapore 981
Ashburn 721
Houston 601
Woodbridge 595
Fairfield 591
Ann Arbor 447
San Jose 436
Warsaw 430
Hong Kong 353
Chandler 351
Hefei 331
Trieste 311
Wilmington 300
Jacksonville 264
Seattle 260
Seoul 249
Amsterdam 228
Cambridge 218
Beijing 208
Munich 133
Princeton 133
Boardman 130
Columbus 113
The Dalles 108
Izmir 107
Los Angeles 107
Chicago 102
Milan 97
Ho Chi Minh City 92
Santa Clara 91
Dublin 90
Hanoi 87
London 85
Buffalo 84
Lauterbourg 84
New York 79
Sofia 77
Council Bluffs 75
Zgierz 74
Moscow 67
Helsinki 62
Frankfurt am Main 59
Menlo Park 58
São Paulo 48
Rome 43
North Bergen 42
Shanghai 42
West Jordan 41
Turku 39
Mestre 37
Düsseldorf 36
Brussels 35
Guangzhou 34
Toronto 34
San Diego 33
Verona 32
Tokyo 30
Sacile 26
Vienna 26
Casablanca 25
Abidjan 23
Da Nang 23
Bremen 22
Brooklyn 22
Phoenix 22
Chennai 21
Falls Church 21
Montreal 21
Orem 21
Brno 20
Haiphong 20
Redwood City 20
Bern 18
Nuremberg 18
Dhaka 17
Pittsburgh 16
New Delhi 15
Tashkent 15
Mumbai 14
Zurich 14
Fremont 13
Jakarta 13
Rio de Janeiro 13
Udine 13
Cairo 12
Camerino 12
Codroipo 12
Des Moines 12
Istanbul 12
Manchester 12
Philadelphia 12
Poplar 12
Torre Del Greco 12
Atlanta 11
Baghdad 11
Bologna 11
Nairobi 11
Norwalk 11
Padova 11
Totale 13.758
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]-1,3,5-triazine nucleus: a possible template for adenosine receptor subtypes. 857
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype 761
[1,2,4]Triazolo[1,5-a][1,3,5]Triazine Derivatives as Antagonists for the Adenosine Receptors: a Preliminary Study on Affinity at the A3 Subtype 714
1,2,4]Triazolo[1,5-c]pyrimidines as New Potent Human A3 Adenosine Receptor Antagonists. 675
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 660
[1,2,4]Triazolo[1,5-c]pyrimidine Nucleus as Adenosine Receptor Antagonists: Shift in Selectivity from A2A to A3 Adenosine Receptors. 634
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines 618
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives 441
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment 439
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition 397
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 355
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 291
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study 286
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 280
Advances in Computational Techniques to Study GPCR-Ligand Recognition 271
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases 251
null 245
Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δinhibitors 244
Mixed-reversible and covalent kinase inhibition as a possible new strategy to treat neuro-inflammatory/degenerative diseases 243
N8-Isopentyl and N8-Phenylethyl Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives as Adenosine Receptor Antagonists 242
Chemical probes for the adenosine receptors 237
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 236
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems 226
A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4- d ]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists 223
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View? 218
null 217
Structural investigations on a novel class of 1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptor antagonists. 215
null 214
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonists as a potential anti-Parkinson multitarget approach. 210
Chapter 1: A3 adenosine receptor ligands in the treatment of inflammation and cancer 210
Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy 208
null 197
"Dual Anta-Inhibitors" of the A(2A) Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 194
A Computational Workflow for the Identification of Novel Fragments Acting as Inhibitors of the Activity of Protein Kinase CK1δ 179
Adenosine Receptor Ligands, Probes, and Functional Conjugates: A 20-Year History of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidines (PTP) 179
Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies 178
5-Alkylamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines. Influence of the Substituent on the Affinity at the Adenosine Receptor Subtypes 178
The A3 adenosine receptor as multifaceted therapeutic Target: pharmacology, medicinal Chemistry, and In silico approaches 177
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example 175
Novel fluorescent hA3 adenosine receptor antagonists. 174
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective 170
Fluorescent ligands for the A3 adenosine receptor. 167
Conjugable A3 Adenosine Receptor Antagonists: Probing the 5 Position of the Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Scaffold. 165
CVT 6975-like Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives: an Attempt towards A2B Adenosine Receptor Affinity. 164
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor antagonists: new insights into structure affinity relathionship and receptor antagonist recognition. 163
Anticonvulsivanti 162
The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy 162
null 161
Synthesis and biological evaluation of a new series of 1,2,4-Triazolo(1,5-a)-1,3,5-triazines as human A2A adenosine receptor antagonists with improved water solubility 160
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 158
Structural Investigations on a Novel Class of [1,2,4]Triazolo[1,5-c]pyrimidines as Adenosine Receptor Antagonists. 156
null 154
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists. 154
null 153
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. 151
Conjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes 150
Fluorescent ligands for adenosine receptors 144
Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2Aligand binding kinetics 144
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists 143
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. 142
null 140
Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry. 139
Exploring Directionality of 5-Substitutions in a New Series of 5-Alkyamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptors Antagonists. 137
Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptor Antagonists. 136
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 135
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 134
Simplification of Pyrazolo-triazolo-pyrimidine Nucleus for Searching New Adenosine Receptor Antagonists. 134
Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors 132
7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positions 130
BIOMEDICAL APPLICATIONS I: DELIVERY OF DRUGS 129
Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors 128
Does the combination of optimal substitutions at the C(2)-, N(5)- and N(8)-positions of the pyrazolo-triazolo-pyrimidine scaffold guaranteee selective modulation of the human A(3) adenosine receptors? 126
Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A(3) adenosine receptor antagonists 118
null 116
null 112
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis 108
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective? 106
Functionalized ligands targeting G protein-coupled adenosine receptors 106
FLUORESCENT ANTAGONISTS OF THE A3 ADENOSINE RECEPTOR 104
Recent developments in the field of non peptidic alpha-v beta3 antagonists 103
Promising Targets and Strategies to Control Neuroinflammation (Part II) 102
null 99
Promising Targets and Strategies to Control Neuroinflammation (Part I) 97
null 97
Acyclic purine and pyrimidine nucleotide analogs as ecto-5′-nucleotidase (CD73) inhibitors 95
null 93
null 89
Synthesis and pharmacological characyerization of a new series of 5,7-disubstituted [1,2,4]triazolo[1,5-a] [1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand receptor recognition process. 85
Potent and selective A3adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties 79
Pyrazolo derivatives as potent adenosine receptor antagonists: An overview on the structure-activity relationships 71
null 70
null 70
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: A novel tool to discriminate between the human A2A and A3 receptor bonding sites 68
Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A3 Adenosine Receptor 64
null 63
null 63
Human A3 adenosine receptor as versatile G protein coupled receptor example to validate the receptor homology modeling technology. 63
Receptor Driven Identifications of Novel Human A3 adenosine receptor antagonists as Potential therapeutic agents. 61
Exploring potency and selectivity receptor antagonist profiles using a multilabe classification approach: the human adenosine receptor as a key study 61
null 59
Totale 20.094
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.638
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021124 0 0 0 0 0 0 0 0 0 0 0 124
2021/20221.105 94 100 55 234 19 48 45 28 101 128 46 207
2022/20231.304 118 179 108 178 112 236 9 104 154 28 57 21
2023/20241.086 59 74 70 75 72 92 155 232 4 71 86 96
2024/20252.706 100 107 342 219 191 195 156 133 305 323 210 425
2025/20268.041 665 1.050 2.260 520 373 387 750 195 635 768 258 180
Totale 20.221